CABOZANTINIB

Brand name:

• Cabometyx®

Pharmaceutical company:

Ipsen Pty Ltd

Condition/indication:
(therapeutic use)

• Renal cell carcinoma

PBAC Submission type:

Change to listing (Major submission)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – November 2020

Related medicines:

• CABOZANTINIB

Submission received for:

November 2020 PBAC meeting

Opportunity for consumer comment:

Open 26/08/2020 and close 07/10/2020 (see PBS Website)

PBAC meeting:

Held on 04/11/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

30/11/2020

Lodgement of required documentation:

23/12/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 21/01/2021

Status:

Finalised

Government processes:

Commenced on 30/04/2021

Medicine listed on the PBS:

01/07/2021 (see PBS schedule)

---